Welcome Ali Chaudhry as a PMCOL 401 Student
Ali Chaudhry is a PMCOL 401 Student, which is one of the 400 Level Pharmacology Course at the University of Alberta.
This is an independent research course. "Hands-on" experience is seen as a valuable asset for students graduating from BSc programs. With this in mind, this course provides an opportunity to work with a Faculty member on a research project during the Fall (PMCOL 401) and/or Winter (PMCOL 402) semester.
The student and supervisor will mutually agree upon the details of the project. This is an excellent opportunity to learn current laboratory techniques, data analysis, laboratory notebook maintenance and presentation skills. Literature-based projects may also be available in which the student will be required to identify a research question and meet with the supervisor at regular intervals for discussion and guidance on preparation of a term paper and poster presentation.
Please note that projects must be supervised by primary members of the Department of Pharmacology or adjunct faculty. Students wishing to pursue research in the lab of an unaffiliated faculty are not eligible for this course.
Ali will be examine tissue samples from the heart and brain of previous published articles of vasopressin versus epinephrine and will examine Troponin, Interleukins 1-Beta, 6, and 8, and Tumor-Necrosis-Factor-Alpha in heart tissue and Interleukins 1-Beta, 6, and 8, and Tumor-Necrosis-Factor-Alpha in brain tissue.
His work will contribute to the data on injury markers for the VERSE-Trial.
Ramsie M, Cheung PY, Law B, Schmölzer GM.Resusc Plus. 2023 Aug 31;16:100459. doi: 10.1016/j.resplu.2023.100459. eCollection 2023 Dec.
Summary of our recent published VERSE-Trial Protocol, which will compare Vasopressin and Epinephrine during neonatal cardiopulmonary resuscitation Introduction: Current neonatal resuscitation guidelines recommend the use of epinephrine during neonatal cardiopulmonary resuscitation (CPR). However, newborns receiving epinephrine continue to have high rates of mortality and neurodevelopmental disability. The infrequent need for neonatal CPR, coupled with an inability to consistently anticipate which newborn infants are at risk of requiring CPR, explains the lack of high-quality evidence (i.e., large randomized clinical trials) to better guide healthcare providers in their resuscitative effort. Therefore, we need neonatal data to determine the optimal vasopressor therapy during neonatal CPR. The current pilot trial will examine the efficacy of vasopressin versus epinephrine during CPR of asphyxiated newborn infants. Methods and analysis: The trial will be a prospective, cluster, open label, single-center, randomized controlled trial on two alternative cardiovascular supportive medications. This study will assess the primary outcome of time to return of spontaneous circulation (ROSC) in newborns requiring CPR in the delivery room who were treated with either vasopressin (intervention) or epinephrine (control). Secondary outcomes such as infant mortality and other clinical outcome measures will also be collected. An estimated 20 newborns will be recruited, and comparisons will be made between asphyxiated infants treated with either drugs. Ethics and dissemination: This study has been approved by the Research Ethics Board at the University of Alberta (June 16, 2023). Study findings will be published in peer-reviewed journals, presented at conferences, and communicated to relevant participants and stakeholders.Trial registration: ClinicalTrial.gov Identifier: NCT05738148. Registered February 21, 2023.
https://www.sciencedirect.com/science/article/pii/S2666520423001029?via%3Dihub
Comments